Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Stavudine · 6 trials · 4 indications
| Name | Type | Description |
|---|---|---|
| (A) zidovudine, lamivudine and nevirapine | DRUG | - |
| (B) zidovudine, lamivudine and efavirenz | DRUG | - |
| (C) zidovudine, didanosine, and nevirapine | DRUG | - |
| (D) zidovudine, didanosine, and efavirenz | DRUG | - |
| (E) stavudine, lamivudine, and nevirapine | DRUG | - |
| (F) stavudine, lamivudine and efavirenz | DRUG | - |
| Adherence Strategy Standard of Care (SOC) | PROCEDURE | - |
| Adherence Strategy Community-Based DOT | PROCEDURE | - |
| stavudine, efavirenz, lamivudine | DRUG | - |
| Lamivudine/Zidovudine | DRUG | - |
| Nelfinavir mesylate | DRUG | - |
| Stavudine | DRUG | - |
| Didanosine | DRUG | - |
| Indinavir sulfate | DRUG | - |
| Lamivudine | DRUG | - |
| Zidovudine | DRUG | - |
Inclusion Criteria:(1) HIV infection indicated by (a) positive ELISA in two separate blood samples, the second no more than eight weeks prior to randomization), (b) CD4 cell count of less than 200 cells/ml OR CD4 cell count between 201-350 with plasma HIV-1 RNA level of greater than 55,000 copies/ml...
Stavudine is used to treat HIV infection and AIDS, including AIDS dementia complex. It is a small molecule antiretroviral studied in adult patients with HIV Infections and AIDS. Bristol-Myers Squibb Company developed it under the brand name Zerit, and it has been evaluated both as a single agent and in combination regimens.
Stavudine is developed and manufactured by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company ran the clinical development program for stavudine, including the extended-release Zerit studies and the rollover study for patients completing earlier trials.
Stavudine reached Phase 3 clinical development. Four Phase 3 trials are recorded, all of them completed, with no active trials currently listed. The studies together enrolled about 1,600 participants. The program included randomized designs, and the trials were conducted across the United States, Canada, Botswana, and multiple European, Asian, African, and Latin American countries.
Stavudine was studied in four completed Phase 3 trials: NCT00197613, the Adult Antiretroviral Treatment and Resistance Study in Botswana; NCT00116298, a rollover study for Zerit extended-release trials; NCT00002429, comparing a regimen including coated didanosine; and NCT00002371, testing lamivudine plus stavudine or zidovudine in patients who had taken zidovudine.
No. Stavudine is a distinct drug, though it is often studied and used in combination with efavirenz, lamivudine, and nevirapine. Combination regimens pairing stavudine with lamivudine and nevirapine, or with efavirenz, appear in the clinical literature and trial records, but these are separate antiretroviral agents, not alternative names for stavudine.
Stavudine is also known by the brand name Zerit, and it is frequently referenced in combination regimens such as stavudine, lamivudine, and nevirapine, or stavudine with efavirenz. Those combination labels describe multi-drug regimens rather than separate names for stavudine itself.